Press Releases

May 11, 2021
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
May 11, 2021
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
April 30, 2021
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
April 29, 2021
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
April 15, 2021
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
April 14, 2021
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
March 17, 2021
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 15, 2021
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021
February 16, 2021
Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development
Displaying 1 - 10 of 11